Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

doi:10.1016/j.jhep.2011.03.029

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 高齡福祉養生管理系 > 期刊論文 > Item 310902800/27727

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/27727

標題:	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
作者:	Huang, Chung-Feng Huang, Jee-Fu Yang, Jeng-Fu Hsieh, Ming-Yen Lin, Zu-Yau Chen, Shinn-Cherng Wang, Liang-Yen Juo, Suh-Hang Hank Chen, Ku-Chung Chuang, Wan-Long Kuo, Hsing-Tao Dai, Chia-Yen Yu, Ming-Lung
貢獻者:	老人服務事業管理系
關鍵字:	Hcv Il-28B Tailored Regimen Treatment
日期:	2012
上傳時間:	2014-03-24 15:22:57 (UTC+8)
出版者:	Elsevier Science Bv
摘要:	Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen.Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin.Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p <0.001) and SVR (64.7% vs. 25.6%, p <0.001) rates, and lower relapse rate (28.0% vs. 54.5%, p = 0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/95% confidence intervals [OR/CI]: 6.24/2.34-16.63), followed by lower viral loads (OR/CI: 5.29/2.81-9.93) and age (OR/CI: 0.94/0.919.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22-53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18-9.65), lower viral loads (OR/CI: 2.23/1.00-4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06-1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%.Conclusions: Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
關聯:	Journal of Hepatology v.56 n.1 pp.34-40
顯示於類別:	[高齡福祉養生管理系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	2101	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....